ENPICOM Secures Series B Funding

To scale up operations to meet the high demand for its antibody discovery SaaS Platform

ENPICOM, an innovative bioinformatics software engineering company, today announced closing of a capital investment round led by BOP Capital. With this additional growth capital, the company can support the rapidly expanding customer base for its unique SaaS proposition, the IGX Platform, to boost the candidate selection processes related to therapeutic antibody discovery. ENPICOM saw a rapid market uptake of its Antibody Discovery Module by Pharma, Biotech and CRO’s after launch in early 2021.

The additional funds enable the company to scale at a faster pace in this highly attractive market and continuing to deliver innovative product extensions for improved antibody discovery, characterization, and development.

ENPICOM’s IGX Platform is a powerful cloud solution designed to improve immunogenomics research by guiding the discovery and development of superior biotherapeutics. Tailored to the needs of scientists working in antibody discovery, it offers an intuitive environment to combine and manage sequencing data derived from state-of-the-art sequencing technologies (e.g., Sanger, bulk NGS, and Single Cell), integrate assay data from wet-lab experiments, and predict exposed sequence liabilities. All this information can be incorporated into tailored analysis workflows to support candidate selection and prioritization, and significantly improve efficiency and costs of early-stage R&D.

“We are thrilled with this capital injection to further grow our business. It clearly illustrates the trust of our existing investor group, BOM Brabant Ventures, NextGen Ventures, and Arches Capital, in our team and proposition. With the addition of BOP Capital, we have a great new strategic investor on board.” said Jos Lunenberg, Chief Executive Officer at ENPICOM.

“BOP Capital is very proud to join ENPICOM’s investor base. We believe in impact through technology. This is exactly what we see in ENPICOM’s platform. In combination with exceptional leadership and a strong execution track record, this provides a perfect setup to realize future growth in a highly promising market. We are looking forward to becoming part of their journey and work closely with the Enpicom team in the coming years.” said Jeroen Mensen, Managing Partner at BOP Capital.

 

 

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.